Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND Study

Summary Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative gastro‐oesophageal reflux disease. Aim : To compare the efficacy of ‘on‐demand’ treatment with esomeprazole 20 mg vs. continuous treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics Vol. 20; no. 6; pp. 657 - 665
Main Authors: Tsai, H. H., Chapman, R., Shepherd, A., McKeith, D., Anderson, M., Vearer, D., Duggan, S., Rosen, J. P.
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Science Ltd 15-09-2004
Blackwell
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Summary Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative gastro‐oesophageal reflux disease. Aim : To compare the efficacy of ‘on‐demand’ treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy‐negative gastro‐oesophageal reflux disease. Methods : Endoscopy‐negative gastro‐oesophageal reflux disease patients who achieved complete resolution of heartburn after short‐term (2–4 weeks) treatment with esomeprazole 20 mg (n = 774) were randomized to receive either esomeprazole 20 mg on‐demand (n =311) or lansoprazole 15 mg continuous daily treatment (n = 311) for 6 months. Results : Significantly more patients were willing to continue taking esomeprazole on‐demand than lansoprazole continuous therapy after 6 months (93% vs. 88%; P = 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one‐third (36%). Furthermore, patients receiving esomeprazole 20 mg on‐demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously. Conclusions : In patients with endoscopy‐negative gastro‐oesophageal reflux disease, esomeprazole 20 mg on‐demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously.
AbstractList Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative gastro‐oesophageal reflux disease. Aim : To compare the efficacy of ‘on‐demand’ treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy‐negative gastro‐oesophageal reflux disease. Methods : Endoscopy‐negative gastro‐oesophageal reflux disease patients who achieved complete resolution of heartburn after short‐term (2–4 weeks) treatment with esomeprazole 20 mg ( n  = 774) were randomized to receive either esomeprazole 20 mg on‐demand ( n  =311) or lansoprazole 15 mg continuous daily treatment ( n  = 311) for 6 months. Results : Significantly more patients were willing to continue taking esomeprazole on‐demand than lansoprazole continuous therapy after 6 months (93% vs. 88%; P  = 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one‐third (36%). Furthermore, patients receiving esomeprazole 20 mg on‐demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously. Conclusions : In patients with endoscopy‐negative gastro‐oesophageal reflux disease, esomeprazole 20 mg on‐demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously.
Summary Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative gastro‐oesophageal reflux disease. Aim : To compare the efficacy of ‘on‐demand’ treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy‐negative gastro‐oesophageal reflux disease. Methods : Endoscopy‐negative gastro‐oesophageal reflux disease patients who achieved complete resolution of heartburn after short‐term (2–4 weeks) treatment with esomeprazole 20 mg (n = 774) were randomized to receive either esomeprazole 20 mg on‐demand (n =311) or lansoprazole 15 mg continuous daily treatment (n = 311) for 6 months. Results : Significantly more patients were willing to continue taking esomeprazole on‐demand than lansoprazole continuous therapy after 6 months (93% vs. 88%; P = 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one‐third (36%). Furthermore, patients receiving esomeprazole 20 mg on‐demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously. Conclusions : In patients with endoscopy‐negative gastro‐oesophageal reflux disease, esomeprazole 20 mg on‐demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously.
Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy-negative gastro-oesophageal reflux disease. To compare the efficacy of 'on-demand' treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy-negative gastro-oesophageal reflux disease. Endoscopy-negative gastro-oesophageal reflux disease patients who achieved complete resolution of heartburn after short-term (2-4 weeks) treatment with esomeprazole 20 mg (n = 774) were randomized to receive either esomeprazole 20 mg on-demand (n =311) or lansoprazole 15 mg continuous daily treatment (n = 311) for 6 months. Significantly more patients were willing to continue taking esomeprazole on-demand than lansoprazole continuous therapy after 6 months (93% vs. 88%; P = 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one-third (36%). Furthermore, patients receiving esomeprazole 20 mg on-demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously. In patients with endoscopy-negative gastro-oesophageal reflux disease, esomeprazole 20 mg on-demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously.
Author Duggan, S.
Vearer, D.
Rosen, J. P.
Chapman, R.
Shepherd, A.
McKeith, D.
Anderson, M.
Tsai, H. H.
Author_xml – sequence: 1
  givenname: H. H.
  surname: Tsai
  fullname: Tsai, H. H.
– sequence: 2
  givenname: R.
  surname: Chapman
  fullname: Chapman, R.
– sequence: 3
  givenname: A.
  surname: Shepherd
  fullname: Shepherd, A.
– sequence: 4
  givenname: D.
  surname: McKeith
  fullname: McKeith, D.
– sequence: 5
  givenname: M.
  surname: Anderson
  fullname: Anderson, M.
– sequence: 6
  givenname: D.
  surname: Vearer
  fullname: Vearer, D.
– sequence: 7
  givenname: S.
  surname: Duggan
  fullname: Duggan, S.
– sequence: 8
  givenname: J. P.
  surname: Rosen
  fullname: Rosen, J. P.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16098821$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/15352914$$D View this record in MEDLINE/PubMed
BookMark eNqNkc9u1DAQhy1URLeFV0C-cEywnTh_kDisllKQWopEOVsTZzbNKrGj2IHdnirxArwbb9Anweku7RVfbHm--TSa3wk5MtYgIZSzmIfzdhPzJJORYEkWC8bSmAkuZbx9RhaPhSOyYCIrI1Hw5JicOLdhjGU5Ey_IMZeJFCVPF-TPmbM9DiPc2g6pYPd3v_qGWnN_97vGHkxNW0d7OyIFrXHwUAXMWzqAb9F4R_0NGKqt8a2Z7ORoB8bZfz4u977WBA5pZ00TxB7HnvbQGo8GjEZq1xRNbZ22wy7UDTbB_gNpA86PNvxYDM4baBA6OuK6m7aPA7x7MK-uLi-XXz7Qb36qdy_J8zV0Dl8d7lPy_ePZ9epTdHF1_nm1vIi05FxGMmFQlxoqLkpMWIqaF5BhCjKvINMVZjXL87ysUl2JShQ6K4SQPBc8bBvrIjklxd6rR-tcmEsNY9vDuFOcqTkntVFzHGqOQ805qYec1Da0vt63DlPVY_3UeAgmAG8OADgN3XoMi2rdE5exsigED9z7Pfez7XD33wOo5dfr-ZX8BT5aulg
CitedBy_id crossref_primary_10_1007_s12171_007_0027_8
crossref_primary_10_1590_S0004_28032010000100017
crossref_primary_10_1111_j_1572_0241_2007_01106_x
crossref_primary_10_1590_S0104_42302011000600006
crossref_primary_10_4137_CMT_S4500
crossref_primary_10_3748_wjg_v11_i28_4291
crossref_primary_10_2165_00003495_200868110_00009
crossref_primary_10_3748_wjg_v21_i22_6965
crossref_primary_10_1007_s00535_016_1227_8
crossref_primary_10_1111_j_1365_2036_2005_02637_x
crossref_primary_10_1007_s12328_010_0139_z
crossref_primary_10_1111_j_1365_2036_2005_02611_x
crossref_primary_10_1002_14651858_CD011969_pub2
crossref_primary_10_3109_00365521_2013_878380
crossref_primary_10_1097_00042737_200509000_00009
crossref_primary_10_1159_000327533
crossref_primary_10_1586_1744666X_1_4_511
crossref_primary_10_1007_s11938_007_0073_4
crossref_primary_10_1517_17425250903124363
crossref_primary_10_1016_j_curtheres_2005_08_012
crossref_primary_10_1111_j_1440_1746_2007_05249_x
crossref_primary_10_1155_2018_6417526
crossref_primary_10_1016_S2255_4823_11_70124_2
crossref_primary_10_1016_S0104_4230_11_70124_5
crossref_primary_10_1111_j_1365_2036_2007_03381_x
crossref_primary_10_5056_jnm21095
crossref_primary_10_1097_MD_0000000000012732
crossref_primary_10_2147_ciia_2007_2_1_85
crossref_primary_10_1111_j_1365_2036_2010_04544_x
crossref_primary_10_1016_j_cgh_2024_05_004
crossref_primary_10_1016_j_jval_2013_01_007
crossref_primary_10_1038_nrgastro_2013_50
crossref_primary_10_1185_03007995_2015_1047745
crossref_primary_10_1016_S0399_8320_07_89329_8
crossref_primary_10_2165_00003495_200868070_00004
crossref_primary_10_1053_j_gastro_2008_08_044
crossref_primary_10_1016_j_bpg_2010_09_004
crossref_primary_10_1186_s12876_016_0448_x
crossref_primary_10_2165_00003495_200565001_00007
crossref_primary_10_1590_s0004_2803_24612023_154
crossref_primary_10_4166_kjg_2012_60_4_195
crossref_primary_10_1007_s11938_008_0005_y
crossref_primary_10_1111_j_1365_2036_2005_02490_x
crossref_primary_10_1517_14656566_7_1_47
Cites_doi 10.1136/gut.44.2008.S1
10.1046/j.1365-2036.2003.01423.x
10.3109/00365528909091032
10.1046/j.1365-2036.17.s2.5.x
10.1159/000200911
10.1046/j.1365-2036.2003.01464.x
10.1046/j.1365-2036.2000.00813.x
10.1097/00042737-200208000-00008
10.1016/0895-4356(94)90036-1
10.1007/BF03022115
10.1046/j.1365-2036.2001.00943.x
ContentType Journal Article
Copyright 2004 INIST-CNRS
Copyright_xml – notice: 2004 INIST-CNRS
CorporateAuthor COMMAND Study Group
CorporateAuthor_xml – name: COMMAND Study Group
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1111/j.1365-2036.2004.02155.x
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList CrossRef

MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2036
EndPage 665
ExternalDocumentID 10_1111_j_1365_2036_2004_02155_x
15352914
16098821
APT2155
Genre article
Multicenter Study
Comparative Study
Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EST
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TR2
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YOC
ZZTAW
~IA
~WT
AAJUZ
AAVGM
ABCVL
ABHUG
ABPTK
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
IQODW
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
ID FETCH-LOGICAL-c5115-530ad9cab129e304ec18a6e4a57ba6cbe6d07779b4cb2b28c682251721021ed83
IEDL.DBID 33P
ISSN 0269-2813
IngestDate Fri Nov 22 00:17:49 EST 2024
Sat Sep 28 07:46:35 EDT 2024
Sun Oct 22 16:05:54 EDT 2023
Sat Aug 24 00:51:47 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Human
Gastroesophageal reflux
Enzyme
Esophageal disease
H
Enzyme inhibitor
Antiulcer agent
K
Long term
Proton pump inhibitor
Benzimidazole derivatives
Antisecretory agent
Esomeprazole
Digestive diseases
exchanging ATPase
Hydrolases
Endoscopy
Lansoprazole
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5115-530ad9cab129e304ec18a6e4a57ba6cbe6d07779b4cb2b28c682251721021ed83
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2004.02155.x
PMID 15352914
PageCount 9
ParticipantIDs crossref_primary_10_1111_j_1365_2036_2004_02155_x
pubmed_primary_15352914
pascalfrancis_primary_16098821
wiley_primary_10_1111_j_1365_2036_2004_02155_x_APT2155
PublicationCentury 2000
PublicationDate 2004-09-15
PublicationDateYYYYMMDD 2004-09-15
PublicationDate_xml – month: 09
  year: 2004
  text: 2004-09-15
  day: 15
PublicationDecade 2000
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
PublicationTitle Alimentary pharmacology & therapeutics
PublicationTitleAlternate Aliment Pharmacol Ther
PublicationYear 2004
Publisher Blackwell Science Ltd
Blackwell
Publisher_xml – name: Blackwell Science Ltd
– name: Blackwell
References 2002; 14
1989; 156
2000; 14
2001
2000
2002; 51
1999; 49
2000; 30
2000; 7
1999; 44
1994; 47
2003; 17
2001; 15
2001; 13
1998; 42
1992; 51
e_1_2_13_12_2
Hungin APS (e_1_2_13_15_2) 1999; 49
e_1_2_13_13_2
e_1_2_13_20_2
e_1_2_13_11_2
e_1_2_13_8_2
e_1_2_13_7_2
e_1_2_13_6_2
Quigley EMM. (e_1_2_13_5_2) 2001; 13
Talley NJ (e_1_2_13_14_2) 2002; 51
Hungin APS (e_1_2_13_10_2) 1999; 49
e_1_2_13_9_2
Baldi F (e_1_2_13_18_2) 2000; 7
e_1_2_13_4_2
e_1_2_13_3_2
e_1_2_13_2_2
Roseveare C (e_1_2_13_17_2) 1998; 42
e_1_2_13_16_2
e_1_2_13_19_2
References_xml – volume: 14
  start-page: 861
  year: 2000
  end-page: 7
  article-title: Esomeprazole provides improved acid control vs. omeprazole inpatients with symptoms of gastro‐oesophageal reflux disease
  publication-title: Aliment Pharmacol Ther
– volume: 42
  issue: Suppl. 1
  year: 1998
  article-title: Alternative day and prn lansoprazole in the maintenance treatment of oesophagitis
  publication-title: Gut
– volume: 15
  start-page: 347
  year: 2001
  end-page: 54
  article-title: Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 months
  publication-title: Aliment Pharmacol Ther
– volume: 156
  start-page: 7
  issue: Suppl.
  year: 1989
  end-page: 13
  article-title: Epidemiology of reflux disease and reflux esophagitis
  publication-title: Scand J Gastroenterol
– volume: 51
  start-page: 24
  issue: Suppl. 1
  year: 1992
  end-page: 49
  article-title: Epidemiology and natural history of gastro‐oesophageal reflux disease
  publication-title: Digestion
– volume: 13
  start-page: S19
  issue: Suppl. 1
  year: 2001
  end-page: 8
  article-title: Non‐erosive reflux disease: part of the spectrum of gastro‐oesophageal reflux disease, a component of functional dyspepsia, or both
  publication-title: Eur J Gastroenterol Hepatol
– volume: 51
  start-page: A230
  issue: Suppl. III
  year: 2002
  article-title: Predictors of treatment response in patients with non‐erosive reflux disease (NERD)
  publication-title: Gut
– volume: 49
  start-page: 463
  year: 1999
  end-page: 4
  article-title: Factors influencing compliance in long‐term proton pump inhibitor therapy in general practice
  publication-title: Br J Gen Pract
– year: 2001
– volume: 47
  start-page: 81
  year: 1994
  end-page: 87
  article-title: Determining the minimal important change in a disease‐specific quality of life questionnaire
  publication-title: J Clin Epidemiol
– volume: 30
  start-page: 243
  year: 2000
  end-page: 53
  article-title: Prevention of relapse of gastro‐oesophageal reflux disease by lansoprazole: 30 mg every other day or 15 mg daily
  publication-title: Acta Endoscopica
– year: 2000
– volume: 17
  start-page: 52
  issue: Suppl. 2
  year: 2003
  end-page: 6
  article-title: Review article: Management of mild and severe gastro‐oesophageal reflux disease
  publication-title: Aliment Pharmacol Ther
– volume: 7
  start-page: 17
  issue: Special Issue 1
  year: 2000
  end-page: 23
  article-title: Efficacy and tolerability of lansoprazole 15 mg as maintenance therapy of GORD
  publication-title: Dis Manage Health Outcomes
– volume: 17
  start-page: 537
  year: 2003
  end-page: 45
  article-title: Non‐erosive reflux disease (NERD) acid reflux and symptom patterns
  publication-title: Aliment Pharmacol Ther
– volume: 44
  start-page: S1
  issue: Suppl. 2
  year: 1999
  end-page: S16
  article-title: An evidence‐based appraisal of reflux disease management the Geneval Workshop Report
  publication-title: Gut
– volume: 14
  start-page: 857
  year: 2002
  end-page: 63
  article-title: Esomeprazole 40 mg and 20 mg is efficacious in the long‐term management of patients with endoscopy‐negative gastro‐oesophageal reflux disease: a placebo‐controlled trial of on‐demand therapy for 6 months
  publication-title: Eur J Gastroenterol Hepatol
– volume: 49
  start-page: 451
  year: 1999
  end-page: 3
  article-title: Long‐term prescribing of proton pump inhibitors in general practice
  publication-title: Br J Gen Pract
– volume: 17
  start-page: 333
  year: 2003
  end-page: 41
  article-title: Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results
  publication-title: Aliment Pharmacol Ther
– ident: e_1_2_13_9_2
  doi: 10.1136/gut.44.2008.S1
– ident: e_1_2_13_4_2
  doi: 10.1046/j.1365-2036.2003.01423.x
– volume: 49
  start-page: 451
  year: 1999
  ident: e_1_2_13_10_2
  article-title: Long‐term prescribing of proton pump inhibitors in general practice
  publication-title: Br J Gen Pract
  contributor:
    fullname: Hungin APS
– ident: e_1_2_13_16_2
– ident: e_1_2_13_3_2
  doi: 10.3109/00365528909091032
– ident: e_1_2_13_6_2
  doi: 10.1046/j.1365-2036.17.s2.5.x
– ident: e_1_2_13_2_2
  doi: 10.1159/000200911
– ident: e_1_2_13_12_2
  doi: 10.1046/j.1365-2036.2003.01464.x
– volume: 7
  start-page: 17
  issue: 1
  year: 2000
  ident: e_1_2_13_18_2
  article-title: Efficacy and tolerability of lansoprazole 15 mg as maintenance therapy of GORD
  publication-title: Dis Manage Health Outcomes
  contributor:
    fullname: Baldi F
– ident: e_1_2_13_11_2
  doi: 10.1046/j.1365-2036.2000.00813.x
– volume: 42
  issue: 1
  year: 1998
  ident: e_1_2_13_17_2
  article-title: Alternative day and prn lansoprazole in the maintenance treatment of oesophagitis
  publication-title: Gut
  contributor:
    fullname: Roseveare C
– ident: e_1_2_13_7_2
  doi: 10.1097/00042737-200208000-00008
– ident: e_1_2_13_13_2
  doi: 10.1016/0895-4356(94)90036-1
– volume: 49
  start-page: 463
  year: 1999
  ident: e_1_2_13_15_2
  article-title: Factors influencing compliance in long‐term proton pump inhibitor therapy in general practice
  publication-title: Br J Gen Pract
  contributor:
    fullname: Hungin APS
– ident: e_1_2_13_19_2
  doi: 10.1007/BF03022115
– ident: e_1_2_13_20_2
– ident: e_1_2_13_8_2
  doi: 10.1046/j.1365-2036.2001.00943.x
– volume: 51
  start-page: A230
  year: 2002
  ident: e_1_2_13_14_2
  article-title: Predictors of treatment response in patients with non‐erosive reflux disease (NERD)
  publication-title: Gut
  contributor:
    fullname: Talley NJ
– volume: 13
  start-page: S19
  issue: 1
  year: 2001
  ident: e_1_2_13_5_2
  article-title: Non‐erosive reflux disease: part of the spectrum of gastro‐oesophageal reflux disease, a component of functional dyspepsia, or both
  publication-title: Eur J Gastroenterol Hepatol
  contributor:
    fullname: Quigley EMM.
SSID ssj0006702
Score 2.0234816
Snippet Summary Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with...
Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy-negative...
Background : Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy‐negative...
SourceID crossref
pubmed
pascalfrancis
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 657
SubjectTerms 2-Pyridinylmethylsulfinylbenzimidazoles
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Ulcer Agents - administration & dosage
Anti-Ulcer Agents - adverse effects
Biological and medical sciences
Digestive system
Esomeprazole - administration & dosage
Esomeprazole - adverse effects
Esomeprazole - analogs & derivatives
Gastroenterology. Liver. Pancreas. Abdomen
Gastroesophageal Reflux - drug therapy
Humans
Lansoprazole
Medical sciences
Middle Aged
Patient Satisfaction
Pharmacology. Drug treatments
Single-Blind Method
Treatment Outcome
Title Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND Study
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2036.2004.02155.x
https://www.ncbi.nlm.nih.gov/pubmed/15352914
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fa9swEBdbH8ZgbN2_LvtT9LBXFyuWLHtvoUlpN9IV1sHezMlWQiCRQhxDu6fCvsC-275BP8nu5CRNYA9j7MUYyzrbOkl3J__uJ8beqxF0lQWIpFUqkiMVR5BoHcWlzCqpBMSBMv_0iz7_lvUHRJPzcZ0L0_JDbBbcaGSE-ZoGOJh6d5AHhBZOwSHMOyLrpY7In8SgIWRzJBebSTnVAX6IEUcedTOR7IJ6_ihox1I9mkONjTZqd7vYMlfbLm2wSSdP_ufX7LPHK8-U99qu9JTds-4ZezBc_Xt_zn4Naj-z8wV891PLu_HtzY_ZmHt3e_OzsjNwFZ_UnGC7HErCylBOFl96vmJurTkt0nOCxk9c45uaT9FK-rU8oVp5E4f3WT71boyCyW7wGRCnBRGDWO5H3LrKUy7NNZY7Ow7E5XwM9XLh8Yq3tC8DTpL4Kdik0-Zq8wIfguTjz8Nh77zPCUB5_YJ9PRlcHp9Gqy0hohI9QxWpJIYqL8Ggm2KTWNpSZJBaCUobSEtj0yrWWudGlqZrulmZogOkKMzF9rRVlrxke847-4pxJYxOrMk1oIej0UsUWCuVygijoDKmw8Ra_cW8Zf4otiIm1FZB2qJ9PGURtFVcddjhTj-5q5jGOcYyosMO2o5zV0L8OrmQHZaG_vHXzyp6F5d09vpfK75hD1sYUh4J9ZbtLReNfcfu11VzGMYOHvtnn34Dxr4fIQ
link.rule.ids 315,782,786,1408,27934,27935,46065,46489
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3datswFBZbB9ugdP9ruq3TxW5dLFuy7N2FNiWjTVZYBrszkq2EQCKFOIa2V4W-wN5tb9An2TlykiawizF2Zyzr2NL5l48-EfJJDFUkjFIBN0IEfCjCQMVSBmHB05ILpkIPmd_9Jvs_0pMOwuScrfbCNPgQ6wU31Axvr1HBcUF6W8t9iRbYYJ_nHaH7EkcQUD7iCU9RxOP4Ym2WE-kLECHnyIIoZfF2Wc8fKW35qt2ZqmDahs15FxsOazOo9V7p9Nl_Hc9zsrcMTmm7kaYX5IGxL8nj3vL3-yvyq1O5qZnN1bWbGBqFdze30xF19u7mZ2mmypZ0XFGs3KWqwHIZ3JZFF44uwVsriuv0FKvjx7Z2dUUn4Cjdih4TDb2xhecMnTg7AsLoOuhUIawFYoMY6obU2NLhdporaLdm5LHL6UhVi7mDO87g0QxgJ2EoMKeT-nL9AZ895eOvvV67f0KxhvLqNfl-2hkcd4PlqRBBAcGhCEQcqjIrlIZIxcQhNwVLVWK4ElKrpNAmKUMpZaZ5oSMdpUUCMZDATBfm05Rp_IbsWGfNPqGCaRkbnUkFQY6EQJFBr4QLzbRQpdYtwlb8z2cN-Ee-kTQBt3LkFh7lyXPPrfyyRQ63BOW-YxJmkM6wFnnbSM59C0LsZIy3SOIF5K_flbcvBnh18K8dP5In3UHvPD__0j97R542VUlZwMR7srOY1-YDeViV9aFXpN8NNiJR
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LitswFBXtFIZC6Xva9DHVolsPli1ZdndhkjB9JA10Ct0ZyZZDIJFCHMNMVwP9gf5b_2C-pPfKSSaBLkrpzljWtfW858pHR4S8FZWKhFEq4EaIgFciDFQsZRAWPC25YCr0kvlnX-ToW9rro0zOh81emFYfYrvghiPDz9c4wBdltT_IPUMLpmAf5p2g9xIngCfvcEDlSO-L4_F2Vk6k5x9CyJEFUcrifVbPHy3tuap7C1VDrVXtcRc7_moX03qnNHjwP4vzkNxfQ1PabfvSI3LL2MfkcLj--f6E_OrXbm4WS_XdzQyNwuurH_MJdfb66mdp5sqWdFpT5O1SVSBZBjdl0ZWja-nWmuIqPUVu_NQ2rqnpDNyk29hjorU3tfCcoTNnJ2AYHQedKxS1QGUQQ11FjS0dbqa5hHRrJl65nE5UvVo6uOMMHswAsyQUBap01lxsP-Cdt3z6eTjsjnoUGZSXT8nXQf_89CxYnwkRFAANRSDiUJVZoTTgFBOH3BQsVYnhSkitkkKbpAyllJnmhY50lBYJICCBcS7UpynT-IgcWGfNc0IF0zI2OpMKII4EmMggV8KFZlqoUusOYZvmzxet9Ee-EzJBa-XYWniQJ899a-UXHXK8109uMiZhBsEM65Bnbce5SUGBnYzxDkl8__jrd-Xd8TlevfjXjG_I4bg3yD-9H318Se62lKQsYOIVOVgtG_Oa3K7L5tgPo99toSD3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Esomeprazole+20%E2%80%83mg+on%E2%80%90demand+is+more+acceptable+to+patients+than+continuous+lansoprazole+15%E2%80%83mg+in+the+long%E2%80%90term+maintenance+of+endoscopy%E2%80%90negative+gastro%E2%80%90oesophageal+reflux+patients%3A+the+COMMAND+Study&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Tsai%2C+H.+H.&rft.au=Chapman%2C+R.&rft.au=Shepherd%2C+A.&rft.au=McKeith%2C+D.&rft.date=2004-09-15&rft.pub=Blackwell+Science+Ltd&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=20&rft.issue=6&rft.spage=657&rft.epage=665&rft_id=info:doi/10.1111%2Fj.1365-2036.2004.02155.x&rft.externalDBID=10.1111%252Fj.1365-2036.2004.02155.x&rft.externalDocID=APT2155
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon